In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Central and Eastern Europe: Opportunity Abounds

Executive Summary

The size of the drug market in those Central and Eastern European countries set to join the European Union in May 2004 is no bigger than that of Canada and is smaller than any of the top five EU markets, for now. But growth in the region will continue to outstrip that in the West over the coming five years at least, according to IMS Global Consulting. The likely convergence of drug usage patterns with those in the West-particularly the increased use of innovative products-will add to the region's attractiveness. Many Big Pharma and mid-sized Europeans are already well placed to tap into the opportunity, but there's plenty of room for newcomers to join-particularly through acquisition.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts